After a median follow-up of 3.3 years, 2.9% of patients developed a second lymphoproliferative disorder, and this was not associated with CLL biological characteristics, such as ZAP70 or CD38 expression, IGHV mutational status or cytogenetic aberrations. The gene discussed is ZAP70; the disease is B-cell chronic lymphocytic leukemia.